| Name | Title | Contact Details |
|---|
Blue Matter Consulting is a management consulting firm dedicated to the life sciences industry, particularly in pharmaceuticals and biotechnology. Founded in 2012, the company has grown from a single office to a global presence with locations in the United States, Europe, and India. The leadership team, including managing partners Ashwin Dandekar, Emily Hua, and George Schmidt, guides the firms strategic growth. The firm offers a wide range of services to help life sciences companies maximize value. These services include new product planning, launch strategy and management, commercial strategy for existing products, market access strategy, corporate strategy, transaction support, and organizational design. Blue Matter also focuses on specific therapeutic areas such as oncology and rare diseases, providing tailored strategies and solutions. With a diverse client base of over 250 companies, including many top global biopharmaceutical firms, Blue Matter Consulting is recognized for its strategic expertise and personalized service in the life sciences sector.
TermScout is a Denver-based legal-tech company that helps businesses review contracts smarter and faster.
OMi Cranes provides one of the few 100% turnkey solutions for your overhead lifting needs. We are a true overhead crane manufacturer, not just an assembler of others components. Whether providing a standard offering or completely customized solution, we know what works to fit your needs and budget. With over 30 years of industry experience, we provide the reliability for customers depend on. OMi Crane Systems, Inc. is a active member of Crane Manufacturers Association of America (CMAA). CMAA is an affiliate of the United States Division of Material Handling Industry (MHI). OMi Crane Systems, Inc. builds cranes to comply with OSHA standards, as well as CMAA and NEC specifications.
Synonym is accelerating the worlds biological future by developing, financing and building commercial-scale biomanufacturing facilities. We provide synthetic biology (synbio) producers – from startups to the Fortune 500 – with flexible production capacity while giving infrastructure investors access to a new, carbon-negative biomanufacturing asset class that we are calling "fermentation farms".